GlassScriptPhysician profile
Gregg O Coodley
NPI 1871593491
$3,181.64
in general payments reported to CMS, 2019-2025
30 companies · $803 in 2025
The $803 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $156 · 2021: $233 · 2022: $439 · 2023: $774 · 2024: $618 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,194.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $597.77 | 2020-2025 | Dovato, Apretude, Cabenuva |
| Amgen INC. | $416.60 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $285.67 | 2021-2025 | Qulipta |
| Lilly USA, LLC | $228.64 | 2021-2025 | Jardiance, Emgality, Zepbound |
| Gilead Sciences, INC. | $197.00 | 2019-2025 | Veklury |
| Glaxosmithkline, LLC. | $186.27 | 2022-2025 | Arexvy, Shingrix, Nucala |
| Merck Sharp & Dohme LLC | $186.02 | 2020-2024 | Pifeltro, Delstrigo, Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.59 | 2021-2024 | Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $164.61 | 2020-2025 | |
| Abbott Laboratories | $100.59 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Astrazeneca Pharmaceuticals LP | $65.73 | 2022-2024 | Fasenra, Airsupra, Breztri |
| Vanda Pharmaceuticals INC. | $62.01 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.38 | 2022-2025 | |
| Exact Sciences Corporation | $56.31 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $52.45 | 2019-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $51.41 | 2021 | |
| Novo Nordisk INC | $31.40 | 2021-2024 | Wegovy |
| Lundbeck LLC | $28.47 | 2022 | |
| Dexcom, INC. | $27.91 | 2025 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $27.26 | 2019-2020 | |
| Medtronic USA, INC. | $25.92 | 2019 | |
| Braemar Manufacturing, LLC | $23.87 | 2019 | |
| Janssen Pharmaceuticals, INC | $22.06 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.81 | 2021 | |
| Amarin Pharma, INC. | $15.01 | 2020 | |
| Hologic Sales and Service, LLC | $15.00 | 2025 | Thinprep 2000 Processor |
| Kowa Pharmaceuticals America, INC. | $14.95 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.84 | 2021 | |
| Philips North America LLC | $13.47 | 2019 | |
| Allergan, INC. | $12.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregg Coodley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.